Page last updated: 2024-12-05

5-chlorouracil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-Chlorouracil is a synthetic analog of uracil, a pyrimidine base found in DNA and RNA. It is synthesized by chlorination of uracil. 5-chlorouracil is a potent inhibitor of thymidylate synthase, an enzyme essential for DNA synthesis. It is an important research tool for studying DNA replication and repair, and has been investigated as a potential anticancer agent. 5-chlorouracil can also be used as a probe in various biological studies, including the analysis of nucleic acid structure and function.'

5-chlorouracil : An organochlorine compound consisting of uracil having an chloro substituent at the 5-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID15758
CHEMBL ID144082
CHEBI ID60762
SCHEMBL ID42227
MeSH IDM0056765

Synonyms (60)

Synonym
7lq4v03rny ,
unii-7lq4v03rny
5-chloro-1h-pyrimidine-2,4-dione
2,3h)-pyrimidinedione, 5-chloro-
5-chlorouracil
nsc28172
uracil, 5-chloro-
1820-81-1
nsc-28172
NCI60_002298
2,4(1h,3h)-pyrimidinedione, 5-chloro-
inchi=1/c4h3cln2o2/c5-2-1-6-4(9)7-3(2)8/h1h,(h2,6,7,8,9
5-chloropyrimidine-2,4(1h,3h)-dione
5-chlorouracil, reagentplus(r), 99%
ai3-26560
einecs 217-339-7
nsc 28172
uracil, 5-chloro- (van)
CHEMBL144082
AKOS003093906
5-chloro-2,4-dihydroxypyrimidine
CHEBI:60762 ,
AKOS003242135
5-chloranyl-1h-pyrimidine-2,4-dione
A812650
AKOS006222774
FT-0604354
EPITOPE ID:138111
5-chloro-2,4-pyrimidinedione
fluorouracil impurity e [ep impurity]
chlorouracil, 5-
AM83916
SCHEMBL42227
210369-56-5
5-chloro-2,4(1h,3h)-pyrimidinedione #
5uc ,
W-107804
mfcd00006019
164415-64-9
4(3h)-pyrimidinone, 5-chloro-2-hydroxy- (9ci)
5-chloro-uracil
DTXSID7075137
AC-8694
5-chlorouracil, vetec(tm) reagent grade, 98%
CS-0010970
5-chlorouracil (fluorouracil impurity)
5-chloropyrimidine-2,4(1h,3h)-dione (5-chlorouracil)
SY028182
107577-08-2
2,4-pyrimidinediol, 5-chloro- (9ci)
AS-10925
Q238482
SB57723
fluorouracil impurity e
EN300-96343
5-chloro-1,2,3,4-tetrahydropyrimidine-2,4-dione
2(1h)-pyrimidinone,5-chloro-4-hydroxy-(9ci)
PD121670
Z1203730752
HY-I0959

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" While there were minor differences seen in food consumption, water consumption and erythroid parameters between the 3-month and the 12-month studies, it was concluded that there were no adverse effects seen on these parameters nor on body weight, EKG, clinical laboratory studies and organ weights."( Toxicity study of uracil in dogs.
Morita, K; Richter, WR; Spicer, EJ, 1985
)
0.27

Dosage Studied

ExcerptRelevanceReference
" The suitability and robustness of the method for in vivo samples were confirmed by analysis of mouse plasma, muscle and tumour from animals dosed with 5-FU."( Hydrophilic interaction liquid chromatography-APCI-mass spectrometry determination of 5-fluorouracil in plasma and tissues.
Breda, M; Grassi, S; James, CA; Pisano, R, 2005
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID96642Cytostatic activity against proliferation of L1210/0 cells (murine leukemia L1210 cells)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis, structure, and antitumor and antiviral activities of a series of 5-halouridine cyclic 3',5'-monophosphates.
AID165909Cytostatic activity against proliferation of Raji/TK cells (deoxythymidine kinase deficient Raji cells)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis, structure, and antitumor and antiviral activities of a series of 5-halouridine cyclic 3',5'-monophosphates.
AID96643Cytostatic activity against proliferation of L1210/BdU cells (deoxythymidine kinase deficient L1210 cells)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis, structure, and antitumor and antiviral activities of a series of 5-halouridine cyclic 3',5'-monophosphates.
AID165908Cytostatic activity against proliferation of Raji/0 cells (human lymphoblast Raji cells)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis, structure, and antitumor and antiviral activities of a series of 5-halouridine cyclic 3',5'-monophosphates.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (37)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (21.62)18.7374
1990's3 (8.11)18.2507
2000's11 (29.73)29.6817
2010's14 (37.84)24.3611
2020's1 (2.70)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.70 (24.57)
Research Supply Index3.69 (2.92)
Research Growth Index4.91 (4.65)
Search Engine Demand Index30.68 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (5.13%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other37 (94.87%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]